38 related articles for article (PubMed ID: 26437693)
1. Exploring p53 protein expression and its link to TP53 mutation in myelodysplasia-related malignancies-Interpretive challenges and potential field of applications.
Bedekovics J; Madarász K; Mokánszki A; Molnár S; Mester Á; Miltényi Z; Méhes G
Histopathology; 2024 Jul; 85(1):143-154. PubMed ID: 38571438
[TBL] [Abstract][Full Text] [Related]
2. Clonal hematopoiesis with TET2 mutations spawning synchronous primary central nervous system lymphoma and myelodysplastic syndrome.
Treiber H; Ganster C; Schanz J; Shimono J; Zechel S; Pohanyar N; Riedel C; Stadelmann C; Haase D; Trümper L; Chapuy B; Wulf GG
Ann Hematol; 2023 Dec; 102(12):3631-3633. PubMed ID: 37702823
[No Abstract] [Full Text] [Related]
3. TP53-Mutated Myelodysplastic Syndrome: A Diagnostic Approach in Different Clinical Settings.
Kaseb H; Crane G; Gibson J
Genet Test Mol Biomarkers; 2024 Jun; 28(6):219-222. PubMed ID: 38708593
[No Abstract] [Full Text] [Related]
4. ERCC6L2 syndrome: attack of the TP53 clones.
Wlodarski MW
Blood; 2023 Jun; 141(23):2788-2789. PubMed ID: 37289478
[No Abstract] [Full Text] [Related]
5. Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia.
Martins F; Kruszewski M; Scarpelli I; Schoumans J; Spertini O; Lübbert M; Blum S
Ann Hematol; 2021 Jan; 100(1):63-78. PubMed ID: 32556451
[TBL] [Abstract][Full Text] [Related]
6. Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.
Burgos S; Montalban-Bravo G; Fuente L; Jabbour EJ; Kanagal-Shamanna R; Soltysiak KA; Garcia-Manero G; Mela-Osorio MJ
Medicine (Baltimore); 2019 Jan; 98(1):e14011. PubMed ID: 30608448
[TBL] [Abstract][Full Text] [Related]
7. Significance of JAK2 and TET2 mutations in myelodysplastic syndromes.
Hellström-Lindberg E
Blood Rev; 2010 Mar; 24(2):83-90. PubMed ID: 20171768
[TBL] [Abstract][Full Text] [Related]
8. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
Guo J; Chang CK; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
[TBL] [Abstract][Full Text] [Related]
9. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.
Jain P; Tang G; Konoplev SN; Kanagal-Shamanna R; Wang SA; Pemmaraju N; Daver N; Estrov Z
Am J Hematol; 2016 Mar; 91(3):354-5. PubMed ID: 26437693
[No Abstract] [Full Text] [Related]
10. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
11. A Rare Episode of Extensive Bone Marrow Necrosis in a Chemotherapy-naïve Patient with Multiple Myeloma Exhibiting
Jeon K; Kim HJ; Kim M; Lee YK
Ann Clin Lab Sci; 2020 Jan; 50(1):136-139. PubMed ID: 32161023
[TBL] [Abstract][Full Text] [Related]
12. Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in
Tobiasson M; Pandzic T; Cavelier L; Sander B; Wahlin BE
Leuk Lymphoma; 2019 Dec; 60(13):3316-3319. PubMed ID: 31204875
[No Abstract] [Full Text] [Related]
13. Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.
Kim M; Yahng SA; Kwon A; Park J; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Lee SH; Kim YJ
Bone Marrow Transplant; 2015 Aug; 50(8):1132-4. PubMed ID: 25961778
[No Abstract] [Full Text] [Related]
14. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in the 5q- Syndrome.
Pellagatti A; Boultwood J
Mediterr J Hematol Infect Dis; 2015; 7(1):e2015037. PubMed ID: 26075044
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
